Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Dodd

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The AAPS Journal|September 27, 2020
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry PerspectiveArian Emami Riedmaier, Kevin DeMent, James Huckle, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 InhibitorsQian Zhao, James R Manning, James Sutton, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorYoung Shin Cho, Julian R Levell, Gang Liu, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of NVP-LDE225, a Potent and Selective Smoothened AntagonistShifeng Pan, Xu Wu, Jiqing Jiang, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The AAPS Journal|September 27, 2020
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry PerspectiveArian Emami Riedmaier, Kevin DeMent, James Huckle, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 InhibitorsQian Zhao, James R Manning, James Sutton, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorYoung Shin Cho, Julian R Levell, Gang Liu, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of NVP-LDE225, a Potent and Selective Smoothened AntagonistShifeng Pan, Xu Wu, Jiqing Jiang, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Pageof 2